Pharmacological Properties of Thalidomide and its Analogues

Author(s): Juan B. De Sanctis, Michael Mijares, Alirica Suarez, Reinaldo Compagnone, Jenny Garmendia, Dolores Moreno, Margarita Salazar-Bookaman

Journal Name: Recent Patents on Inflammation & Allergy Drug Discovery
Continued as Recent Advances in Inflammation & Allergy Drug Discovery

Volume 4 , Issue 2 , 2010


Thalidomide and its immunomodulatory imide drugs (IMiDs) analogues CC-5013 (Revlimid™, Lenalidomide) and CC-4047 (Actimid™, Pomalidomide) have been used as anti-inflammatory and anticancerous drugs in the recent years. Thalidomide and IMiDs inhibit the cytokines tumour necrosis factor-α (TNF-α), interleukins (IL) 1β, 6, 12, and granulocyte macrophage-colony stimulating factor (GM-CSF). They also costimulate primary human T, NKT and NK lymphocytes inducing their proliferation, cytokine production, and cytotoxic activity. On the other hand, the compounds are anti-angiogenic, anti-proliferative, and pro-apoptotic. Thalidomide analogues have been used as inhibitors of α glucosidase and could be potential drugs for diabetes treatment. In this review, we explore the current trend of the different structures, the new patents, and the possible new applications in different pathologies.

Keywords: Thalidomide, IMiDs, lenalidomide, revlimid, actimid, pomalidomide, cytokines, Multiple myeloma, Prostate cancer, Angiogenesis, Diabetes

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2010
Published on: 01 March, 2012
Page: [144 - 148]
Pages: 5
DOI: 10.2174/187221310791163026
Price: $65

Article Metrics

PDF: 10